Daniel Cho covers the business and financial dimensions of biotechnology and healthcare, with an emphasis on how investment trends reflect deeper shifts in innovation and risk. His reporting explores capital allocation, strategic deals, and market signals across the life sciences. At The Catalyst Brief, Daniel connects financial activity to scientific progress and policy developments to provide a more complete view of the industry.
148 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Regulatory & PolicyThe judge's ruling maintains access to mifepristone through mail-order prescriptions for now, reflecting the complex regulatory landscape surrounding abortion medication. The FDA’s review may influence future policy decisions and availability.
Daniel ChoApr 8, 2026
Regulatory & PolicyIn February 2026, a small biotech company nearing a clinical trial agreement with the FDA faced an unexpected four-month postponement that ultimately led to its closure. This incident highlights challenges that news and stakeholders in the biotech industry frequently encounter due to protracted regulatory processes.
Daniel ChoApr 6, 2026
Healthcare InvestmentThe health technology arena continues to attract substantial capital, with key players securing investments to advance digital health solutions, medical devices, and AI-driven platforms. This overview highlights four notable funding announcements that underscore ongoing trends and potential industry shifts.
Daniel ChoApr 4, 2026
Biopharmaceutical IndustryInitially designed to produce hundreds of millions of vaccines annually, BioNTech's Singapore facility will now be shuttered as the company adapts to evolving market conditions and pipeline priorities. This move reflects broader challenges faced by mRNA technology in the U.S. and a transition to different therapeutic modalities.
Daniel ChoApr 3, 2026
Regulatory & PolicyA newly surfaced draft order reveals that the U.S. government is considering imposing a full 100% tax on some imported medications as a strategy to support domestic pharmaceutical manufacturing and address trade imbalances. Such a policy could have broad implications across the healthcare and pharmaceutical industries, patient affordability, and international trade relations affecting drug availability and pricing dynamics.
Daniel ChoApr 2, 2026
Regulatory & PolicyThe health savings account industry has launched a vigorous lobbying campaign aimed at broadening access to HSAs. This push echoes the momentum gained from the Trump administration’s tax reforms and has sparked discussions on potential policy changes impacting consumer health financing options.
Daniel ChoMar 31, 2026
Biopharmaceutical IndustryIn a significant biopharmaceutical industry move, Biogen announced its acquisition of Apellis Pharmaceuticals for $5.6 billion upfront. This acquisition aims to bolster Biogen’s presence in immunology, a critical and growing therapeutic area with unmet medical needs.
Daniel ChoMar 31, 2026
AI in Drug DiscoveryMass General Brigham has established a rigorous process for deciding which artificial intelligence tools are worth deploying across their health system. This careful evaluation aims to balance innovation with patient safety and operational effectiveness.
Daniel ChoMar 31, 2026
AI in Drug DiscoveryThe application of artificial intelligence in rural healthcare settings is helping bridge gaps in specialist availability. By integrating Eko Health’s AI-enabled digital stethoscope, Wayne General Hospital exemplifies how technology can improve early detection of heart disease in underserved areas.
Daniel ChoMar 25, 2026
Biopharmaceutical IndustryThe pandemic has reshaped biotech funding in ways that many may not recognize at first glance. Companies eager for a rebound must instead adapt to the new environment, recalibrating strategies and expectations in order to thrive.
Daniel ChoMar 24, 2026
Medical TechnologyMassachusetts has witnessed a staggering rise in recorded sepsis hospitalizations since 2010, with cases tripling according to recent reports. This surge has generated debate on whether such trends represent a true escalation in sepsis incidence or are tied to the adoption of advanced AI tools for medical coding and billing practices. Examining this phenomenon offers insight into the broader implications of AI integration in healthcare administrative processes and patient care documentation.
Daniel ChoMar 20, 2026
Biopharmaceutical IndustryJohnson & Johnson's newly approved pill represents a milestone in psoriasis treatment, providing patients a daily oral alternative to current injectable therapies. This approval has the potential to disrupt the existing treatment landscape and address patient preferences for less invasive medication options.
Daniel ChoMar 18, 2026